ライフサイエンスコーパス: cardiovascular

1 Cardiovascular alterations were monitored by advanced sp

2 e the effect of acute avocado pulp intake on cardiovascular and autonomic recovery subsequent to mode

3 certain, low-imminence threat while blunting cardiovascular and behavioral anticipatory arousal to hi

4 sis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, und

5 At 5 years, the incidence of major adverse cardiovascular and cerebrovascular events was higher in

6 s previously published statements addressing cardiovascular and cerebrovascular risk and disparities

7 hich indeed has already been demonstrated by cardiovascular and gastrointestinal symptoms.

8 and flow probes were implanted to determine cardiovascular and metabolic changes during uterine hand

9 , a proinflammatory compound associated with cardiovascular and neurological diseases.

10 sociated with lower mortality risk from both cardiovascular and noncardiovascular causes in low-, mid

11 To assess the subsequent incidence of cardiovascular and renal disease events, follow-up infor

12 Cardiovascular and renal outcomes with empagliflozin in

13 ents with diabetes, SGLT2 inhibitors improve cardiovascular and renal outcomes, including hospitaliza

14 All-cause, non-cardiovascular, and cardiovascular hospitalizations were

15 ns, malignancies, and death regarding liver, cardiovascular, and malignant disease, as well as all-ca

16 rticipant factors associated with all-cause, cardiovascular, and non-cardiovascular hospitalizations

17 ents were stratified by the 2019 Society for Cardiovascular Angiography and Interventions (SCAI) shoc

18 bly, rs6008845 T/T homozygotes experienced a cardiovascular benefit from fibrate even in the absence

19 provide a better understanding of ncRNAs in cardiovascular biology we present an outlook on speciali

20 have indirectly improved HF care quality and cardiovascular care costs, but these models are not focu

21 Cardiopulmonary Resuscitation and Emergency Cardiovascular Care is based on the extensive evidence e

22 The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with

23 This suggests that the profile of cardiovascular changes noted in adults with SDB may also

24 ifference, 11.2%) and a higher prevalence of cardiovascular comorbidities.

25 associated with multiple direct and indirect cardiovascular complications including acute myocardial

26 em of obesity and its multiple metabolic and cardiovascular complications threatens the health and lo

27 er therapies can lead to a broad spectrum of cardiovascular complications.

28 protected from obesity-induced metabolic and cardiovascular complications.

29 patients with early atrial fibrillation and cardiovascular conditions.

30 atients with hypercholesterolemia or related cardiovascular conditions.

31 We quantified the individual and interactive cardiovascular consequences of these reflexes during exe

32 This review summarizes cardiovascular considerations related to marijuana use,

33 rocytes, as these cells reside alongside the cardiovascular control circuits and mediate increases in

34 Key efficacy outcomes were MACE (cardiovascular [CV] death, myocardial infarction, stroke

35 he risk of heart failure hospitalization and cardiovascular death in patients with heart failure and

36 eling, and reduce hospitalization for HF and cardiovascular death in patients with type 2 diabetes me

37 ither trial was powered to assess effects on cardiovascular death or all-cause death or to characteri

38 ventional therapy on the primary endpoint of cardiovascular death or hospital admission for heart fai

39 No significant difference in the risk of cardiovascular death was observed for patients with and

40 and direction of the factors associated with cardiovascular death were minimally changed.

41 (median 516 days), the combined endpoint of cardiovascular death, all-cause stroke, myocardial infar

42 major bleeding, 0.54 (95% CI, 0.39-0.76) for cardiovascular death, and 0.80 (95% CI, 0.72-0.88) for a

43 R) for major vascular events (a composite of cardiovascular death, myocardial infarction or other acu

44 ociated with lower rates of all-cause death, cardiovascular death, rehospitalization for heart failur

45 vents) of heart failure hospitalizations and cardiovascular death.

46 EF >5% and ESV 10%) and heart failure event/cardiovascular death.

47 0 831 deaths were documented, including 3819 cardiovascular deaths and 761 respiratory deaths.

48 y a CEC in the SHIFT study confirmed most of cardiovascular deaths and worsening HF hospitalizations

49 n bacterial infection, inflammation, wounds, cardiovascular defects and cancer.

50 sal cardiovascular function and on the fetal cardiovascular defense responses to acute stress.

51 t given overlap between COVID-19 and typical cardiovascular diagnoses such as heart failure and acute

52 erythematosus predispose to atherosclerotic cardiovascular disease (ASCVD).

53 ion are major players in the pathogenesis of cardiovascular disease (CVD) and Alzheimer's disease (AD

54 Secondary outcomes were cardiovascular disease (CVD) and cancer mortality.

55 ic blood pressures provide information about cardiovascular disease (CVD) but are only extremes of th

56 Inflammation plays an important role in cardiovascular disease (CVD) development.

57 us (HIV) may affect the risk of death due to cardiovascular disease (CVD) differently in men versus w

58 Cardiovascular disease (CVD) has become an increasingly

59 Cardiovascular disease (CVD) is the leading cause of dea

60 Cardiovascular disease (CVD) is the leading cause of dea

61 ciate with composite and individual incident cardiovascular disease (CVD) outcomes including myocardi

62 ucing saturated fat (SFA) intake to decrease cardiovascular disease (CVD) risk, but there is limited

63 pants (mean age 62.5 +/- 11.7 years) without cardiovascular disease (CVD) were recruited from the Car

64 mption and smoking, 2 major risk factors for cardiovascular disease (CVD), often occur together.

65 respiratory infections are risk factors for cardiovascular disease (CVD).

66 arbohydrate intake may determine the risk of cardiovascular disease (CVD).

67 dyslipidemia treatment in those at risk for cardiovascular disease (CVD).

68 s (T2D) is associated with increased risk of cardiovascular disease (CVD).

69 which are associated with increased risk of cardiovascular disease (CVD).

70 ich the RVLM could contribute chronically to cardiovascular disease (CVD).

71 with and without history of atherosclerotic cardiovascular disease (CVD).

72 2.48; 95% CI, 1.21-5.05), history of pre-LT cardiovascular disease (HR, 2.19; 95% CI, 1.2-3.98), and

73 cular outcomes in patients with a history of cardiovascular disease (moderate strength) or diabetes m

74 ll as a firmly established increased risk of cardiovascular disease and chronic kidney disease in tho

75 conduct and analysis of clinical trials for cardiovascular disease and heart failure.

76 rial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein chole

77 o guide counseling of affected families with cardiovascular disease and may guide primary interventio

78 nsion is a common modifiable risk factor for cardiovascular disease and mortality.

79 mean 24-hour BP associated with high risk of cardiovascular disease and progression of kidney disease

80 rial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) leve

81 holesterolemia is characterized by premature cardiovascular disease caused by markedly elevated level

82 on, smoking, and family history of premature cardiovascular disease contributed to progression, with

83 As cardiovascular disease decreases in many countries, mort

84 These variations mean that the profile of cardiovascular disease differs between low-income and hi

85 has also emerged as a therapeutic target for cardiovascular disease due to its ability to remodel car

86 Worryingly, the prevalence of acquired cardiovascular disease during pregnancy is rising as old

87 equires a team approach to the management of cardiovascular disease during pregnancy.

88 The individual-level risk of atherosclerotic cardiovascular disease events in primary prevention popu

89 es in symptom classification with subsequent cardiovascular disease events.

90 e that diets with protective effects against cardiovascular disease exert an anti-atherothrombotic ef

91 As the mechanism accounting for cardiovascular disease is prevalently due to the atherot

92 High awareness that cardiovascular disease is the leading cause of death (LC

93 Among adults aged 35-70 years, cardiovascular disease is the major cause of mortality g

94 ional age offspring are at increased risk of cardiovascular disease later in life.

95 participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and i

96 nd low grip strength had stronger effects on cardiovascular disease or mortality than in HICs.

97 mendations for prevention of atherosclerotic cardiovascular disease rely principally on estimated 10-

98 HIV-related cardiovascular disease research is predominantly from Eu

99 in obese adolescents and are associated with cardiovascular disease risk factors, HsCRP and Ox-LDL.

100 ultivariable adjustment for demographics and cardiovascular disease risk factors.

101 pment of type 2 diabetes (T2D) and increases cardiovascular disease risk.

102 contradicted previous conclusions on EPA for cardiovascular disease risk.

103 assessment and management of atherosclerotic cardiovascular disease risk.

104 Finally, cardiovascular disease susceptibility genes identified u

105 n approach can be expanded to apply to other cardiovascular disease targets and emerging therapeutic

106 es mellitus without clinical atherosclerotic cardiovascular disease to guide the use of preventive ph

107 The incidence of major cardiovascular disease was associated with increased ris

108 In 2015-2018, cardiovascular disease was the most common cause of deat

109 than did placebo among participants without cardiovascular disease who were at intermediate cardiova

110 ESA participants (n = 4,184 subjects free of cardiovascular disease), PA was measured by waist-secure

111 diabetes, 15 on adverse birth outcomes, 8 on cardiovascular disease, 3 each on obesity and rheumatoid

112 tudy (HPFS; 1986-2016) who were free of T2D, cardiovascular disease, and cancer at baseline.

113 iplatelet therapy reduces ischemic events in cardiovascular disease, but it increases bleeding risk.

114 n various pathological conditions, including cardiovascular disease, cancer, diabetes and chronic neu

115 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension.

116 m cancer are now more common than those from cardiovascular disease, indicating a transition in the p

117 s, and plays a crucial role in hypertension, cardiovascular disease, kidney disease, and fluid homeos

118 high-risk population of older patients with cardiovascular disease, randomization to ramipril had no

119 ABO blood group is associated with cardiovascular disease, with significantly lower risk in

120 edge of the genetic basis of atherosclerotic cardiovascular disease-in particular, coronary artery di

121 singly prevalent modifiable risk factors for cardiovascular disease.

122 hould not be used in high-risk patients with cardiovascular disease.

123 e myocardial trabeculae on susceptibility to cardiovascular disease.

124 s in the comorbidity of major depression and cardiovascular disease.

125 impaired glucose metabolism, contributes to cardiovascular disease.

126 ntal cause of poor health and disparities in cardiovascular disease.

127 a major causal factor in the development of cardiovascular disease.

128 rticularly HXP and LXP) impact upon risk for cardiovascular disease.

129 , and clinical trials targeting PCSK9 reduce cardiovascular disease.

130 co-specific therapeutics in the treatment of cardiovascular disease.

131 )) are associated with an increased risk for cardiovascular disease.

132 linical condition that accelerates renal and cardiovascular disease.

133 Aortic stiffness is closely linked with cardiovascular diseases (CVDs), but recent studies sugge

134 Cardiovascular diseases (CVDs), principally ischemic hea

135 diseases with an immune component, including cardiovascular diseases and susceptibility to infections

136 hose with two conditions in addition to T2D, cardiovascular diseases featured in 18 of the top 20 com

137 Advanced phenotyping of cardiovascular diseases has evolved with the application

138 DAD) study has reported an increased risk of cardiovascular diseases in people with human immunodefic

139 causal role of alcohol consumption for other cardiovascular diseases requires further research.

140 ning health implications of cannabis include cardiovascular diseases, although they may be mediated b

141 ounting evidence implicating inflammation in cardiovascular diseases, attempts at clinical translatio

142 Ischemic cardiovascular diseases, particularly acute myocardial i

143 Disruption of BMP signaling can trigger cardiovascular diseases, such as arteriovenous malformat

144 and degenerative diseases including cancer, cardiovascular diseases, type 2 diabetes mellitus, obesi

145 tween obesity, type 2 diabetes mellitus, and cardiovascular diseases.

146 isk factor for obesity, type 2 diabetes, and cardiovascular diseases.

147 ammatory bowel disease, neurologic diseases, cardiovascular disorders, and cancer.

148 at altitude, by linking genetic factors with cardiovascular dynamics, as evaluated by phase coherence

149 The cardiovascular effects of ertugliflozin, an inhibitor of

150 PPARA regulatory variant that influences the cardiovascular effects of fenofibrate and that could be

151 class are strong predictors of the in vitro cardiovascular effects of PCBs.

152 FAs did not significantly reduce the primary cardiovascular end point of major CVD events (composite

153 [95% CI, 0.26-0.97]) but not stroke or other cardiovascular end points.

154 opurinol therapy with respect to the primary cardiovascular endpoint, and its long-term use is not as

155 nge, 54 to 81 years]) and 11.7% had an acute cardiovascular event.

156 .69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-index=0.65 [0.61-0.69] for PCI

157 Secondary outcomes included major adverse cardiovascular events (death, myocardial infarction, str

158 en shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone

159 se (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those without

160 th early-stage breast cancer who experienced cardiovascular events after cancer diagnosis had increas

161 ffects of yoga-based CR (Yoga-CaRe) on major cardiovascular events and self-rated health in a multice

162 Cardiovascular events are among the leading cause of mor

163 echanisms through which NSAIDs cause adverse cardiovascular events are not entirely understood.

164 Arterial cardiovascular events are the leading cause of death in

165 id (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy i

166 d an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.

167 o an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls

168 Genetic risk scores were not associated with cardiovascular events in 357 882 unrelated individuals f

169 ssociations between LGE presence and adverse cardiovascular events in patients with dilated cardiomyo

170 ill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participant

171 iations between eGFR, cardiac mechanics, and cardiovascular events were partly mediated via CFR.

172 bserved in the primary outcome (composite of cardiovascular events).

173 e 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00) for majo

174 d 2842 controls matched by age, a history of cardiovascular events, and cancer type.

175 ial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboemb

176 esterol (LDL-C) is associated with increased cardiovascular events, especially in high-risk populatio

177 poprotein (LDL) cholesterol results in fewer cardiovascular events.

178 oprotein(a) concentration is associated with cardiovascular events.

179 are at high risk for major adverse limb and cardiovascular events.

180 nce of high-risk coronary plaque and risk of cardiovascular events.

181 he inpatient management of adults with acute cardiovascular events.

182 he effects of glucocorticoids on fetal basal cardiovascular function and on the fetal cardiovascular

183 ior hypoglycemic effect while also improving cardiovascular function for the patients.

184 VEGF-A and PDGF signalling in vitro, but its cardiovascular function in vivo remains relatively unexp

185 Changes in parameters and predicted cardiovascular function post-transplant are used to eval

186 f weight loss to have a meaningful impact on cardiovascular health and survival is unknown.

187 anchored in an understanding that to achieve cardiovascular health for all, the AHA must include a br

188 d smoking marijuana carries many of the same cardiovascular health hazards as smoking tobacco.

189 sity is characterized by specific additional cardiovascular health issues that should receive attenti

190 s include addressing fertility preservation, cardiovascular health, and survivorship issues, along wi

191 flexes maintain autonomic balance and ensure cardiovascular health.

192 risk and even future targets for optimizing cardiovascular health.

193 minal plasma specific programming effects on cardiovascular health.

194 failure in the ICU, related to five groups (cardiovascular, hematology, pulmonary, renal, and endocr

195 thnicity was associated with higher risk for cardiovascular hospitalization [rate ratio (RR) 1.25, 95

196 The Kaplan-Meier estimate of freedom from cardiovascular hospitalization was 84.2% (95% CI, 80.2%-

197 ated with all-cause, cardiovascular, and non-cardiovascular hospitalizations during a median follow u

198 All-cause, non-cardiovascular, and cardiovascular hospitalizations were associated with old

199 cardiography and the European Association of Cardiovascular Imaging guidelines for predicting elevate

200 herefore, new criteria based on contemporary cardiovascular imaging parameters are needed.

201 eld, new core criteria based on contemporary cardiovascular imaging parameters are proposed for the a

202 rdware advances in CT and their relevance to cardiovascular imaging.

203 ocardial infiltration, device infection, and cardiovascular inflammation are successfully gaining cli

204 that they arise across distinct contexts of cardiovascular inflammation.

205 n January 2017 and April 2020 in the British Cardiovascular Intervention Society database.

206 Cardiovascular magnetic resonance (CMR) included gadobut

207 ejection fraction <40%) referred for stress cardiovascular magnetic resonance (CMR) may have a less

208 tics Consortium (n = 188,577) and UK Biobank Cardiovascular Magnetic Resonance substudy (n = 16,923)

209 pies have remained an unfulfilled promise in cardiovascular medicine until today.

210 Cytotoxic CD4 T cells are linked to cardiovascular morbidities and accumulate in both HIV an

211 igh blood pressure (BP) is a risk factor for cardiovascular morbidity and mortality.

212 the progression to end-stage kidney failure, cardiovascular morbidity, and premature death.

213 rot) and PMI(UD) were associated with 5-year cardiovascular mortality (adjusted hazard ratio [HR]: 2.

214 lopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% C

215 ard ratio [HR], 1.49 [CI, 1.15 to 1.94]) and cardiovascular mortality (HR, 1.66 [CI, 1.07 to 2.57]) i

216 Results were also null for cardiovascular mortality in the 2 external cohorts (eg,

217 positively associated with AMI incidence and cardiovascular mortality with all four methods.

218 s associated with renal function decline and cardiovascular mortality.

219 ssociated with a lower risk of all-cause and cardiovascular mortality.

220 h as echocardiography, bone scintigraphy and cardiovascular MRI.

221 Addressing the complex cardiovascular needs of these patients has become increa

222 development on prognosis compared with other cardiovascular or renal diagnoses in patients with T2D.

223 intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries

224 pendently associated with higher risk of the cardiovascular outcome and the kidney outcome, but not w

225 Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER]; NCT01179048).

226 es in oncology, a large prospective clinical cardiovascular outcome study investigating the BET inhib

227 In large cardiovascular outcome trials in patients with diabetes,

228 This resulted in a plethora of new cardiovascular outcome trials, most designed primarily a

229 ce in light of the findings of the completed cardiovascular outcome trials.

230 ts of an HLA-DR1 donor also have an impaired cardiovascular outcome.

231 eport the effect of finerenone on individual cardiovascular outcomes and in patients with and without

232 olic volume index (LAESVI) is a predictor of cardiovascular outcomes and is the recommended measureme

233 f the oft-cited issue of sodium reduction on cardiovascular outcomes and then propose a framework for

234 the impact of self-measured BP monitoring on cardiovascular outcomes are needed.

235 In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Perc

236 In the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Perc

237 d with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation

238 Evidence on reducing SBP for cardiovascular outcomes in patients with a history of ca

239 assessing the effects of SGLT2 inhibitors on cardiovascular outcomes in patients with HFrEF with or w

240 nsortium (MINICOR [Multi-Modal International Cardiovascular Outcomes Registry]).

241 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors i

242 was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients w

243 (daytime cognitive function) and long-term (cardiovascular outcomes).

244 ol abuse can also influence both hepatic and cardiovascular outcomes.

245 ver more important to optimize our patients' cardiovascular outcomes.

246 tcome of interest was reduction in composite cardiovascular outcomes.

247 ificantly associated with increased risk for cardiovascular outcomes.

248 nhibitors have a favorable effect on certain cardiovascular outcomes.

249 over novel mechanisms and molecular bases of cardiovascular pathophysiological manifestations.

250 g evidence linking sphingolipid biology with cardiovascular pathophysiology, these results suggest th

251 , and their relationship to other indices of cardiovascular performance.

252 aortic valve is an important determinant of cardiovascular physiology and anatomic location of commo

253 kinases (PKGs) play important roles in human cardiovascular physiology, regulating vascular tone and

254 ficant increase in per-capita utilization of cardiovascular prescription drugs among Medicaid benefic

255 procedural success and outcomes of all major cardiovascular procedures.

256 aspirin regimen of 75 to 100 once daily for cardiovascular prophylaxis appears to be largely inadequ

257 osis, prognosis of, or treatment decision in cardiovascular, pulmonary, and metabolic diseases.

258 1%; hazard ratio, 0.91 [95% CI, 0.88-0.95]), cardiovascular readmission (19.7% versus 22.9%; hazard r

259 roke and modestly lower 1-year all-cause and cardiovascular readmissions.

260 results in significant interactions between cardiovascular reflexes, with the impact differing when

261 sympathetic dysregulation, thereby improving cardiovascular regulation and immunity long after SCI.SI

262 hree hypothalamic subsystems are involved in cardiovascular regulation in humans.

263 lf5), an essential transcriptional factor of cardiovascular remodeling, mediates the link between mit

264 patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple o

265 vidual psychosocial resilience, neighborhood cardiovascular resilience, and LS7 scores.

266 ure with total mortality and cause-specific (cardiovascular, respiratory, and non-accidental) mortali

267 Transiently heightened cardiovascular risk around the 2016 election may be attr

268 allopurinol, and had at least one additional cardiovascular risk factor.

269 rtunately, current interventions that target cardiovascular risk factors (such as anti-hypertensive d

270 ed in this study, correlated with almost all cardiovascular risk factors and estimated risk.

271 High signal intensities correlate with cardiovascular risk factors and metabolic disease.

272 After adjusting for age, gender, and cardiovascular risk factors, only mean oxygen saturation

273 and improved management of blood glucose and cardiovascular risk factors.

274 Objectives: To evaluate the effect of OSA on cardiovascular risk for patients with different ACS phen

275 such as dietary AGE restriction, may reduce cardiovascular risk in CKD, but this requires testing in

276 le of intestinal phosphate binders to reduce cardiovascular risk in patients with CKD who have normop

277 To date, although a less favorable cardiovascular risk profile for Diclofenac as compared t

278 In patients at increased cardiovascular risk receiving metformin-based background

279 tibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that ev

280 Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) is a randomized, double-blind, mult

281 he gut microbiome may be warranted to reduce cardiovascular risk, particularly in individuals with pr

282 addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a

283 basis of 12 clinical factors associated with cardiovascular risk.

284 diovascular disease who were at intermediate cardiovascular risk.

285 nd its manifestations in individuals at high cardiovascular risk.

286 ing the link between mutations and increased cardiovascular risk.

287 tween marijuana and a broad range of adverse cardiovascular risks.

288 ps to provide clearer guidance regarding its cardiovascular safety.

289 ion post-transplant are used to evaluate the cardiovascular state during recovery of five patients.

290 r lifelong (>25 years) endurance exercise on cardiovascular structure and exercise function have been

291 X-1 in platelets and in the remainder of the cardiovascular system and linked them to anti- and pro-t

292 The cardiovascular system exhibits strong circadian rhythms

293 ellular organ that intimately links with the cardiovascular system to accomplish gas exchange.

294 rious human diseases, including those of the cardiovascular system.

295 n failure, especially of the respiratory and cardiovascular systems.

296 ed proteomic analysis to identify additional cardiovascular targets of miR-144, and subsequently exam

297 ollowed by sequencing method in two of three cardiovascular tissues.

298 ed in COVID-19 are unlikely to cause serious cardiovascular toxicity.

299 applications could be catheters tailored to cardiovascular, urological, gastrointestinal, and neurov

300 2019 (COVID-19) pandemic exposes unexpected cardiovascular vulnerabilities and the need to improve c